AR 301

Drug Profile

AR 301

Alternative Names: AR 301 (anti-Sa mAb) - Aridis Pharmaceuticals; AR-301 - Aridis Pharmaceuticals; KBSA-301; Salvecin

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Kenta Biotech
  • Class Antibacterials; Monoclonal antibodies
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pneumonia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sepsis; Staphylococcal infections
  • Phase I/II Pneumonia

Most Recent Events

  • 01 Sep 2016 Aridis completes a phase-I/IIa clinical trial for Pneumonia and Staphylococcal infections (Adjunctive treatment) in USA, United Kingdom, Belgium, France and Spain (NCT01589185)
  • 24 Feb 2016 Aridis Pharmaceuticals receives patent allowance for AR 301 in Europe before February 2016
  • 24 Feb 2016 Aridis Pharmaceuticals receives patent allowance for AR 301 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top